{"entity":{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","aka":[],"tldr":"Governments and foundations would pool a prize of about a billion dollars into an escrowed fund, paid only when a treatment is shown in a well-controlled registration cohort to keep most patients with a currently incurable metastatic cancer, such as pancreatic adenocarcinoma or glioblastoma, disease-free for five years. The winner keeps its patent but accepts a price ceiling.","summary":"A pull incentive that pays for the outcome the system currently under-rewards. The prize is defined in advance per disease (for example metastatic pancreatic adenocarcinoma, glioblastoma, metastatic TNBC) with an objective bar such as at least 50% five-year disease-free survival in a randomised or well-controlled registration cohort where the historical figure is under 5%. The winner keeps its patent but accepts a price ceiling and global access licensing as a condition. Multiple sponsors could pool into a single escrowed fund; a partial prize could be paid for intermediate milestones (for example 25% durable remission).","asOf":"2026-09-08","links":[{"label":"XPRIZE","url":"https://www.xprize.org/"},{"label":"Longitude Prize","url":"https://longitudeprize.org/"}],"tags":[],"related":["idea-fund-first-in-class-prize","idea-fund-value-based-patent-extension"],"cancers":["pancreatic","glioblastoma","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-metastasis-biology"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A credible, escrowed cure prize of one billion dollars or more per disease increases the number of registered first-in-class programmes in the named diseases by at least half within five years and attracts new entrants (academic spin-outs, non-oncology companies) that the current market does not.","rationale":"Pull mechanisms have worked where the goal is well-specified and the market signal weak: the Ansari X Prize, the Longitude Prize, Gavi's advance market commitment and DARPA challenges. Current oncology rewards are indifferent to magnitude of benefit, so capital flows to predictable incremental gains; a prize inverts the payoff curve for the hardest problems.","test":"Announce a single-disease prize with a fully escrowed fund and pre-registered success criteria, then track new programme registrations, venture funding and phase 1 starts in that disease against matched diseases without a prize over five years.","maturity":"speculative","actor":"policy","cost":"large","horizonYears":10},"route":"/ideas/idea-fund-cure-prize/","neighbours":{"idea":[{"id":"idea-fund-first-in-class-prize","kind":"idea","name":"Milestone prizes for first-in-class mechanisms reaching human proof of concept","route":"/ideas/idea-fund-first-in-class-prize/"},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/"},{"id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/"}],"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"}]}}